Enrolling

A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)

J3Z-MC-OJAE - -

The main purpose of this study is to evaluate the safety and tolerability of LY3884961 (PR001) in adult participants with Type 1 Gaucher Disease.

Enter your city or zip code to find the nearest site

See if You May Qualify

Answer a few questions to see if you meet key criteria for this study.

Trial Summary

Age Range
18 - 65 years
Conditions the trial is for
Gaucher Disease, Type 1
What the trial is testing?
LY3884961
Could I receive a Placebo?
No
Enrollment Goal
15
Trial Dates
Dec 20, 2022 - Oct 2030
How long will I be in the trial?
5 years (1.5 years for the main study period and 3.5 years for the follow-up period)
Trial Phase
II

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Be 18 to 65 years old

  • Have bi-allelic GBA1 gene mutations.  If you do not know your genetic status, centralized testing will be performed

  • On Enzyme Replacement Therapy or Substrate Reduction Therapy

Participants Must Not:

  • Have had complete spleen removal

  • Have a history of significant liver disease

  • Have serious illnesses that could interfere with this study (will be assessed by the investigator)

  • Have taken certain medicines or had certain treatments, such as any type of prior gene or cell therapy

  • Become pregnant or impregnate others during the study

  • Have problems undergoing an MRI

Lilly Trial Alerts

Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.

Clinical Trial Resources